HIV and the Opioid Epidemic: 5 Key Points
This chart series highlights 5 key things to know about the intersection of the nation’s HIV and opioid epidemics.
View the Latest: Prescription Drugs
Filter
-
-
Poll: Public Says Drug Companies Have More Influence in Washington than the NRA
News ReleaseDemocrats Split on Whether to Fix the ACA or Push for a National Health Plan; Few Democratic Voters Say a National Health Plan is Their Top Issue for the Midterms As policymakers weigh strategies to address the high cost of prescription drugs, the latest Kaiser Health Tracking Poll finds that a large majority of the…
-
Kaiser Health Tracking Poll – March 2018: Views on Prescription Drug Pricing and Medicare-for-all Proposals
FeatureMore than a year into President Trump’s presidency, the March Kaiser Health Tracking Poll gauges the public’s top priorities for the president and Congress to do in the coming months. This month’s poll also measures perceptions on the cost of prescription drugs, attitudes towards policymakers’ actions to address drug prices, and views of pharmaceutical companies. In addition, with the 2018 midterm elections less than 8 months away, the KFF poll asks how important a national health plan is to voters.
-
What Initiatives Are States Considering To Control Prescription Drug Costs in Medicaid?
News ReleaseRising Medicaid spending on prescription drugs has prompted many states to look for new ways to control such costs.
-
Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
Issue BriefThis issue brief provides a snapshot of current state initiatives aimed at addressing the cost of prescription drugs in Medicaid.
-
Summary of Recent and Proposed Changes to Medicare Prescription Drug Coverage and Reimbursement
Issue BriefOn February 9, 2018 the President signed into law the Bipartisan Budget Act of 2018, which included some provisions related to Medicare Part D prescription drug coverage. Shortly thereafter, the Office of Management and Budget released the President’s fiscal year (FY) 2019 budget, which also included several proposals related to Medicare Part D drug coverage and Part B drug reimbursement. This brief summarizes these recently enacted and proposed changes.
-
Poll: Nearly 1 in 4 Americans Taking Prescription Drugs Say It’s Difficult to Afford Their Medicines, including Larger Shares Among Those with Health Issues, with Low Incomes and Nearing Medicare Age
News ReleaseAs the Trump Administration and Congress weigh policy options to address high prescription drug prices, a fourth of people taking prescription drugs (24%) and seniors taking drugs (23%) say it is difficult for them to afford their medications, the latest KFF Health Tracking Poll finds.
-
KFF Health Tracking Poll – February 2019: Prescription Drugs
FeatureWith increased national attention towards prescription drug costs, this poll examines the public’s experiences with prescription medicine and their views on current policy proposals brought forth by congressional lawmakers and the Trump administration, including international reference pricing, transparency in drug advertisements, and negotiations with drug companies. The survey also dives into the attitudes and experiences of adults, 65 and older – a group that is more likely to report taking prescription medication and shopped for prescription drug coverage.
-
Analysis Finds that Medications for Hepatitis C and HIV/AIDS Are the Costliest Group of Outpatient Prescription Drugs for Medicaid, While Diabetes Drugs Have Posted the Sharpest Rise in Costs
News ReleaseAntiviral medications, including those that treat hepatitis C and HIV/AIDS, cost the Medicaid program more money (before rebates) than any other group of outpatient prescription drugs for each year from 2014 to 2017, according to a new KFF analysis.
-
Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2014-2017
Issue BriefAlthough the outpatient drug benefit accounts for only 6% of total Medicaid spending, drug spending has increased by double digits in recent years, and is expected to grow faster than most other Medicaid services in the next 10 years. This issue brief examines drug spending and utilization from 2014 through 2017 by drug group, brand and generic status, and biologic status to understand the causes for this increase in spending.